United Capital Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $514K | Buy |
1,575
+43
| +3% | +$14K | ﹤0.01% | 761 |
|
|
2025
Q1 | $414K | Buy |
1,532
+52
| +4% | +$14K | ﹤0.01% | 796 |
|
|
2024
Q4 | $348K | Sell |
1,480
-88
| -6% | -$20.7K | ﹤0.01% | 832 |
|
|
2024
Q3 | $431K | Buy |
1,568
+48
| +3% | +$13.2K | ﹤0.01% | 767 |
|
|
2024
Q2 | $369K | Buy |
+1,520
| New | +$369K | ﹤0.01% | 780 |
|
|
2021
Q3 | – | Sell |
-1,387
| Closed | -$235K | – | 1194 |
|
|
2021
Q2 | $235K | Sell |
1,387
-100
| -7% | -$16.9K | ﹤0.01% | 1095 |
|
|
2021
Q1 | $210K | Sell |
1,487
-1,669
| -53% | -$236K | ﹤0.01% | 1099 |
|
|
2020
Q4 | $410K | Sell |
3,156
-32,560
| -91% | -$4.23M | ﹤0.01% | 895 |
|
|
2020
Q3 | $5.2M | Buy |
35,716
+2,491
| +7% | +$363K | 0.03% | 337 |
|
|
2020
Q2 | $4.92M | Buy |
+33,225
| New | +$4.92M | 0.04% | 363 |
|
|
2016
Q4 | – | Sell |
-4,197
| Closed | -$284K | – | 1252 |
|
|
2016
Q3 | $284K | Hold |
4,197
| – | – | ﹤0.01% | 1092 |
|
|
2016
Q2 | $231K | Sell |
4,197
-53
| -1% | -$2.92K | ﹤0.01% | 1129 |
|
|
2016
Q1 | $267K | Sell |
4,250
-3
| -0.1% | -$188 | ﹤0.01% | 1032 |
|
|
2015
Q4 | $400K | Hold |
4,253
| – | – | ﹤0.01% | 939 |
|
|
2015
Q3 | $342K | Sell |
4,253
-86
| -2% | -$6.92K | ﹤0.01% | 1021 |
|
|
2015
Q2 | $520K | Hold |
4,339
| – | – | 0.01% | 904 |
|
|
2015
Q1 | $442K | Buy |
4,339
+765
| +21% | +$77.9K | 0.01% | 938 |
|
|
2014
Q4 | $347K | Hold |
3,574
| – | – | 0.01% | 927 |
|
|
2014
Q3 | $279K | Buy |
+3,574
| New | +$279K | ﹤0.01% | 951 |
|
|
2014
Q2 | – | Sell |
-3,500
| Closed | -$235K | – | 781 |
|
|
2014
Q1 | $235K | Hold |
3,500
| – | – | 0.01% | 840 |
|
|
2013
Q4 | $225K | Hold |
3,500
| – | – | 0.01% | 578 |
|
|
2013
Q3 | $224K | Buy |
+3,500
| New | +$224K | 0.01% | 611 |
|